Despite a paucity of data regarding both the incidence of ocular candidiasis and the utility of ophthalmic examination in critically ill patients, routine ophthalmic examination is recommended for critically ill patients with candidaemia. The objectives were to estimate the incidence of ocular candidiasis and evaluate whether ophthalmic examination influenced subsequent management of these patients. We conducted a ten-year retrospective observational study. Data were extracted for all ICU patients who were blood culture positive for fungal infection. Risk factors for candidaemia and eye involvement were quantified and details regarding ophthalmic examination were reviewed. Candida species were cultured in 93 patients. Risk factors for ocular candidiasis were present in 57% of patients. Forty-one percent of patients died prior to ophthalmology examination and 2% of patients were discharged before candidaemia was identified. During examination, signs of ocular candidiasis were only present in one (2.9%) patient, who had a risk factor for ocular candidiasis. Based on these findings, the duration of antifungal treatment for this patient was increased. Ocular candidiasis occurs rarely in critically ill patients with candidaemia, but because treatment regimens may be altered when diagnosed, routine ophthalmic examination is still indicated.
1
. The incidence of ocular candidiasis in ambulant patients with C-BSI appears to be declining, with ranges between 1% and 25.8% reported, but there is a paucity of data regarding incidence in critically ill patients [2] [3] [4] [5] [6] [7] [8] [9] [10] . Patients admitted to the ICU are more susceptible to C-BSI, as the majority of patients have a greater number of risk factors related to disease state and/or severity (e.g. renal failure), procedures (e.g. central venous access), and treatments (e.g. broad-spectrum antibiotics and total parenteral nutrition) 3, 4, 9, 11, 12 . Furthermore, such patients may have an altered conscious state due to the disease process and/or drugs administered and thus be unable to report symptoms related to possible ophthalmic involvement. Current teaching and consensus statements recommend that all patients routinely have ophthalmic examination to detect this complication 13, 14 . However, patients with C-BSI in intensive care may represent infections of shorter duration when compared with cohorts of patients presenting from the community. Furthermore, antifungal agents with fewer adverse effects have recently become available, and this may increase the empirical prescription of antifungal drugs and subsequent duration of administration of these drugs in the critically ill 15 . In addition, the increasing use of antifungal agents on a prophylactic basis in at-risk patients has increased 9 . These factors could reduce the incidence of ocular candidiasis and impact on the course of treatment when the diagnosis is made.
A recent retrospective observational study reported that ocular candidiasis was not detected in hospitalised patients (n=83, but the majority were not admitted to the ICU) who had not received an initial ocular examination, but were subsequently examined after receiving two weeks of antifungal treatment 16 . Given that these data suggest treatment may be unaffected by early routine ophthalmic examination, this examination may now be obsolete 6, 9, 10 , particularly in critically ill patients, as C-BSI is strongly predictive of death 17 .
Ophthalmic examination frequently requires an ophthalmology specialist and may be more challenging to perform in the critically ill. Moreover, ocular examination frequently includes pharmacotherapy-induced dilation of the pupils that can temporarily impact on neurological examination of the patient. Therefore, removing the need for routine ophthalmic examination has the potential to improve hospital efficiencies. However, none of the previous studies focused on critically ill patients and, accordingly, interpretation of these data is limited.
The objectives of this study were to describe the incidence of ocular candidiasis in a critically ill cohort and to evaluate whether routine ophthalmic examination altered treatment regimens. The medical notes for all patients with a positive fungal infection were reviewed and data extracted for age, sex, vital signs and risk factors for C-BSI. These were prolonged ICU length of stay (>28 days), APACHE II score >2018, renal failure, haemodialysis, broad-spectrum antibiotics, central venous access, total parenteral nutrition (TPN) administered for >24 hours, immunosuppression, malignancy, severe acute pancreatitis, Candida colonisation at multiple sites, surgery, and transplantation. Risk factors for eye involvement were intravenous drug use, immunosuppression, diabetes mellitus, TPN, transplantation, and alcohol abuse 4 . Data was also extracted for length of invasive ventilation and of hospital and ICU stay, microbiological results, treatment type and duration, ophthalmological review, and discharge or death. As per local protocol, trained ophthalmologists, either consultants or advanced trainees, performed all ophthalmic examinations.
Materials and methods
The protocol was approved by the Royal Adelaide Hospital Research Ethics Committee, who deemed that informed consent was unnecessary (Reference No. HREC/13/RAH/495). All data are presented as median (IQR).
Results
Yeast or fungal bloodstream infection occurred in 96 patients, with Candida species cultured in 93 patients ( Figure 1 ). The majority of patients with candidaemia had either albicans or glabrata species cultured (Table 1) . Data were incomplete in two patients and these data were excluded from further analysis ( Figure 1 ). The median age of patients was 58 years (43 to 70), with the majority of patients male (64%) and mechanically ventilated (76%). The illness severity score (median Acute Physiology and Chronic Health Evaluation II score) of 23 (18 to 28), was consistent with a severely ill cohort. More patients were admitted with a surgical diagnosis than a medical diagnosis (65% versus 35%) and the majority were fed via the enteral nutrition route, with 69 (76%) patients receiving liquid nutrient via the enteral route as their predominant nutrient source. Ten (11%) patients received TPN, five (5%) a combination of enteral and TPN, and four (4%) were ingesting an oral diet throughout their ICU admission. Three (3%) patients did not receive nutritional therapy in the ICU prior to their death.
Risk factors
The time from hospital admission to the first blood culture positively identified was 10 (5 to 19) days and from ICU admission to first positive blood culture was 6 (1 to 11) days. The most frequent risk factors for patients developing a C-BSI were presence of a central venous catheter, receiving broad-spectrum antibiotics, and undergoing surgery during that admission ( Table 2 ). Risk factors for ocular candidiasis were present in 52 (57%) patients, with 39 patients having a single risk factor and 13 having multiple risk factors. The most frequent risk factor for ocular candidiasis was diabetes ( Table 2) .
Antifungal treatment
Twenty patients died prior to treatment of the C-BSI. Initial antifungal treatment varied (fluconazole, n=43; caspofungin, n=15; anidulofungin, n=9; voriconazole, n=2; and amphotericin, n=2) and was changed during the patient's admission in 27 patients. Forty-one out of the seventy-eight (53%) patients who survived to 'clear' their C-BSI had only one positive blood culture and for those patients with more than one positive culture, the median number of days of positive blood cultures was four (two to six) days.
Patient outcomes
Thirty-nine (39/91, 43%) patients died in the ICU (43%) and the length of stay in the ICU was 17.5 (6.75 to 30.5) days. Death before hospital discharge occurred in 50 (50/91, 55%) patients and the length of stay of patients surviving to hospital discharge was 50 (39 to 82) days.
Ophthalmic examination
Thirty-seven (41%) patients died prior to ophthalmic examination, with a median time from positive blood culture to death of four (two to seven) days. Two (2%) patients were discharged from the ICU prior to Candida being identified. Nineteen (21%) patients survived but did not have an ophthalmic examination. Accordingly, only thirtyfive (38%) patients received an ophthalmic examination (Figure 1 ). The median time from positive culture to review was 8 (5 to 14) days. Seven of the patients died after an ophthalmic examination and within their initial course of treatment. Signs of Candida chorioretinitis were present in only one patient (2.9% of patients who received an ophthalmic examination). This patient had presented with acute cholecystitis and pancreatitis, and a single blood sample cultured C. albicans. The patient had several risk factors for C-BSI but only one for eye involvement (diabetes). Fundoscopy revealed endogenous focal chorioretinitis, and consequently the course of fluconazole was increased from 14 days to six weeks. For patients who did not receive ophthalmic examination and survived, hospital records were reviewed and no patients reported visual symptoms or were referred for an ophthalmology opinion either as an inpatient or outpatient following hospital discharge. 
Discussion
The major observations of this study are that ocular candidiasis appears to occur infrequently in critically ill patients with C-BSI, but when diagnosed, its presence has the capacity to alter the treatment administered.
The incidence of ocular candidiasis in this study (i.e. 2.9% of patients who received an ophthalmic examination) is at the lower end of previous estimates. Although cohorts of critically ill patients have not been extensively studied-with recent data particularly sparse-Nolla-Salas et al completed a multi-centre observational study across 29 ICUs in Spain and observed outcomes from 46 critically ill immunecompetent patients (i.e. patients without neutropenia or recent intravenous drug abuse, no patients with severe burn injuries, no patients who had received solid organ transplants and/or had infection with human immunodeficiency virus) with C-BSI who had at least one ophthalmic examination 20 . Nolla-Salas et al reported that six (13%) patients were found to have signs of ocular candidiasis.
The variation in incidence could represent demographic and geographic differences. However, given that the previous data are from more than 20 years ago, this may indicate that the population incidence is reducing over time. The mechanisms underlying such a reduction of ocular candidiasis are uncertain, but it is speculated that improved infection control practices and antibiotic stewardship, greater surveillance for Candida infections, increased use of empirical antifungal agents and/or newer, less toxic antifungal drugs (which could facilitate the earlier initiation or longer duration of use of antifungal drugs) may contribute to the reduction in observed incidence 7 . It is also worth noting that in the current study the only patient with ocular involvement had a very short period of candidaemia, with only one blood culture being positive and a blood culture taken later that day negative. This is in contrast to previous studies, which reported patients with longer periods of candidaemia were at greater risk of ophthalmic involvement 1, 16 .
Limitations
There are limitations to this study. These include the limitations inherent in any retrospective observational study conducted at a single centre. To somewhat counter this, a longer observation period was selected, but the cohort studied remained relatively small (fewer than 100 patients). Furthermore, less than 50% of patients with C-BSI received an ophthalmic examination. The major reason that ophthalmic examination wasn't performed was that the patient died (41% of patients died) while awaiting examination. Twenty-one percent of the initial cohort that survived ICU also did not have an ophthalmic examination and it is acknowledged that these results may have differed if these patients were examined, but hospital records were reviewed in these patients and none had subsequent review by an ophthalmologist, which would suggest that a review in the ICU was unlikely to alter their outcome. Accordingly, while these data suggest that ocular candidiasis is an infrequent complication, this estimate of incidence in the true population is imprecise. Moreover, while the ICU studied was a mixed medical-surgical ICU, and it is likely that these data are reflective of data from other Australian tertiary metropolitan ICUs, these data may not be generalisable to ICUs that have a larger proportion of patients with profound immunosuppression (e.g. due to malignant haematology/oncology or organ transplantation).
It should also be recognised that it was not possible to ascertain whether continuing antifungal treatment (fluconazole) of the one patient with Candida chorioretinitis beyond two weeks influenced the outcome from this condition. Indeed, it is even possible the lesion was due to another infective or an autoimmune process, particularly given the short period of candidaemia. Current recommendations regarding treatment periods for Candida chorioretinitis vary, with some experts advocating that treatment is continued until the resolution of ocular findings 6 , whereas other groups recommend that a two to three week course of antifungal drug is sufficient to achieve a 95% cure rate 1, 16 . Some centres may offer intravitreal antifungal (e.g. amphotericin) ± vitrectomy 7, 21, 22 , but for those patients with choroiditis or endophthalmitis, this is usually undertaken as 'rescue therapy' following failure of systemic antifungal agents. However, in ambulant patients, subsequent visual acuity appears to depend on the site of initial choroiditis, with vision poorer in those with lesions involving the macula 22 . Accordingly, early ophthalmic examination may be indicated to identify those patients with infection involving the macula, with a view to treating this group with vitrectomy and intravitreal amphotericin.
Donahue et al proposed that only patients with risk factors for eye involvement warrant an ophthalmic examination 4 . Data from the current study support this concept. Notwithstanding the concerns that the cohort studied is relatively small and that the complications of ocular candidiasis can be devastating, particularly when infection involves the macula 21 , it does appear that ophthalmic examination can be delayed until 14 days of treatment (assuming that all patients with C-BSI will receive at least 14 days of intravenous antifungal therapy), as this did not change management and avoids examinations that were ultimately not required (7/35 patients died after an ophthalmoscopy examination and within their initial course of treatment). Such an approach is also supported by data from Krishna et al 6 , who reported that initial ophthalmic examination may be unremarkable but signs of ocular candidiasis can be subsequently observed during serial examinations performed at two-week intervals. If, however, clinicians were changing protocols at their institution, an ongoing audit of outcomes would seem prudent.
Conclusion
Based on observational data from a single tertiary-level referral centre, ocular candidiasis now appears to occur only infrequently in patients admitted to an Australian ICU, but because treatment regimens may be altered when diagnosed, ophthalmic examination appears to still be indicated in patients who develop C-BSI and have at least one risk factor for eye involvement. Our data indicate that delaying examination until two weeks of antifungal treatment has been completed may be safe, and, potentially, this is a strategy that has the capacity to reduce the number of examinations that are ultimately required.
